{"id":305,"date":"2014-12-29T09:28:58","date_gmt":"2014-12-29T09:28:58","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=305"},"modified":"2021-07-24T12:56:23","modified_gmt":"2021-07-24T07:26:23","slug":"delveinsights-immunology-based-gene-therapy-reports","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports","title":{"rendered":"DelveInsight\u2019s Immunology based Gene Therapy Reports"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4abb179e58\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4abb179e58\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\/#Gene_Therapy_The_%E2%80%9CHope%E2%80%9D_for_Immunologic_disorders\" >Gene Therapy: The \u201cHope\u201d for Immunologic disorders!<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\/#About_Immunologic_disorders\" >About Immunologic disorders<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\/#Gene_Therapy_Role_in_Immunological_disorders\" >Gene Therapy: Role in Immunological disorders<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\/#Gene_Therapy_The_Market_Scenario\" >Gene Therapy: The Market Scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\/#DelveInsights_Gene_Therapy_Reports\" >DelveInsight\u2019s Gene Therapy Reports<\/a><\/li><\/ul><\/nav><\/div>\n<blockquote>\n<h4 style=\"text-align:center;\"><span class=\"ez-toc-section\" id=\"Gene_Therapy_The_%E2%80%9CHope%E2%80%9D_for_Immunologic_disorders\"><\/span><span style=\"color:#510878;\">Gene Therapy: The \u201cHope\u201d for Immunologic disorders!<\/span><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<\/blockquote>\n<h3><span class=\"ez-toc-section\" id=\"About_Immunologic_disorders\"><\/span><span style=\"color:#02524b;\">About Immunologic disorders<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align:justify;\"><span style=\"color:#003366;\">Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system. In cases of immune system overactivity, the body attacks and damages its own tissues. These diseases decrease the body&#8217;s ability to fight invaders, causing vulnerability to infections. Most immunological diseases are caused by errors (mutations) in specific genes. It has long been the hope that one day it would be possible to cure these diseases by fixing the mutation that causes the disease and thus affect a cure. As a result of the human genome project and similar efforts to map all of the genes present in human beings, we now know the identities of the specific genes involved in many diseases, including the vast majority of immunological diseases. We have finally reached the stage where that long held hope is becoming a reality.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Gene_Therapy_Role_in_Immunological_disorders\"><\/span><span style=\"color:#02524b;\">Gene Therapy: Role in Immunological disorders<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align:justify;\"><span style=\"color:#003366;\">In its broadest sense, gene therapy is the transfer of a gene, or genes to patients, for therapeutic purposes by using vectors as agents of gene transfer and gene expression. Traditional pharmacological approaches to treatment entail the synthesis of small, diffusable compounds given orally or by injection. These approaches have yet to provide ideal agents for use in immunological diseases. Recent research, however, has identified a number of proteins with the potential to improve treatment, but these are difficult to administer long term. Gene therapy provides the opportunity to deliver protein products, as well as therapeutic species of nucleic acids, such as antisense RNA, much more efficiently than traditional methods of drug therapy. Gene therapy\u2019s greatest strength is its ability to produce high, sustained concentrations of therapeutic macromolecules within a defined anatomical location. Thus, making gene therapy an ideal candidate for treating immunological disorders.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Gene_Therapy_The_Market_Scenario\"><\/span><span style=\"color:#02524b;\">Gene Therapy: The Market Scenario<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align:justify;\"><span style=\"color:#003366;\">Collectively, immunological disorders constitute a major, unmet, clinical challenge. Although no single disorder is highly prevalent, there are over 150 of them. Because these diseases are generally incurable and difficult to manage, there is a pressing need for novel approaches to their treatment. As a result the market opportunities for gene therapy in the field of immunological disorders have been reinvigorated by the entry of large biopharmaceutical companies such as Glaxosmithkline, Novartis. etc. which are operating in this domain. Many companies have started investing in and researching on gene therapy as it has the potential to transform many areas of immunological disorders, leading to more rapid development timelines and access to better treatment options within a shorter time frame. However, there are some risks that need to be overcome and safer vectors need to be developed. Various laboratories around the world are working at modifications of the viral vectors in order to improve their safety. Nevertheless, gene therapy must still be regarded as an experimental therapy. It is likely that the inherent problems will be worked out in the coming years and that a larger number of immunological diseases will be cured by gene therapy.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"DelveInsights_Gene_Therapy_Reports\"><\/span><span style=\"color:#02524b;\">DelveInsight\u2019s Gene Therapy Reports<\/span><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align:justify;\"><span style=\"color:#003366;\"><strong>DelveInsight\u2019s Gene Therapy Reports<\/strong> cover the entire gene therapy market insights for immunological disorders including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight\u2019s proprietary market and pipeline analytics which identifies the front runners in this therapeutic area. It also identifies the potential market movers and future regulatory landscape.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gene Therapy: The \u201cHope\u201d for Immunologic disorders! About Immunologic disorders Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system. In cases of immune system overactivity, the body attacks and damages its own tissues. These diseases decrease the body&#8217;s ability to fight invaders, causing [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[173,180,209,258,313,356,386,479,558],"industry":[17225],"therapeutic_areas":[17235,17227],"class_list":["post-305","post","type-post","status-publish","format-standard","hentry","category-articles","tag-collaborations","tag-competitive-landscape","tag-delveinsights-gene-therapy-reports","tag-gene-therapy","tag-immunologic-disorders","tag-licensing-opportunities","tag-market-trends","tag-pipeline-coverage","tag-technology-assessments","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immunologic disorders based Gene Therapy Market Reports | DelveInsight<\/title>\n<meta name=\"description\" content=\"Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunologic disorders based Gene Therapy Market Reports | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-12-29T09:28:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:23+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Immunologic disorders based Gene Therapy Market Reports | DelveInsight","description":"Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports","og_locale":"en_US","og_type":"article","og_title":"Immunologic disorders based Gene Therapy Market Reports | DelveInsight","og_description":"Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system.","og_url":"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2014-12-29T09:28:58+00:00","article_modified_time":"2021-07-24T07:26:23+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports","url":"https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports","name":"Immunologic disorders based Gene Therapy Market Reports | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2014-12-29T09:28:58+00:00","dateModified":"2021-07-24T07:26:23+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Immunological disorders are a dysfunction of the immune system. These disorders cause abnormally low activity or overactivity of the immune system.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/delveinsights-immunology-based-gene-therapy-reports"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight&#039;s Gene Therapy Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Immunologic disorders<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market trends<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pipeline coverage<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">technology assessments<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight&#039;s Gene Therapy Reports<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Immunologic disorders<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">market trends<\/span>","<span class=\"advgb-post-tax-term\">Pipeline coverage<\/span>","<span class=\"advgb-post-tax-term\">technology assessments<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 29, 2014","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 29, 2014 9:28 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=305"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/305\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=305"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=305"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}